Predict your next investment

Corporation
HEALTHCARE | Drug Development
arvelletx.com

See what CB Insights has to offer

Stage

IPO

Total Raised

$207.8M

Investors Count

9

Deal Terms

1

Portfolio Exits

1

Investments

1

Arvelle Therapeutics Funding, Arvelle Therapeutics Valuation & Arvelle Therapeutics Revenue

4 Fundings

Arvelle Therapeutics's latest funding round was a Acquired for on January 4, 2021.

Arvelle Therapeutics's latest post-money valuation is from January 2021.

Sign up for a free trial to see Arvelle Therapeutics's valuations in January 2021 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

1/4/2021

Acquired

$99M

18

5/26/2020

Series A - II

$99M

10

2/14/2019

Series A

$99M

10

2/14/2019

Spinoff / Spinout

10

Date

1/4/2021

5/26/2020

2/14/2019

2/14/2019

Round

Acquired

Series A - II

Series A

Spinoff / Spinout

Amount

$99M

$99M

Investors

Valuation

$99M

Revenue

Sources

18

10

10

10

Arvelle Therapeutics Deal Terms

1 Deal Term

Arvelle Therapeutics's deal structure is available for 1 funding round, including their Acquired from January 04, 2021.

Round

Acquired

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

$99M

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

$99M

$99M

$99M

$99M

Arvelle Therapeutics Investors

9 Investors

Arvelle Therapeutics has 9 investors. Angelini Pharma invested in Arvelle Therapeutics's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

1/4/2021

1/4/2021

1
Acquired

Corporation

Italy

00/00/0000

00/00/0000

Andera Partners

Subscribe to see more

Private Equity

France

00/00/0000

00/00/0000

NovaQuest Capital Management

Subscribe to see more

Private Equity

North Carolina

00/00/0000

00/00/0000

Life Sciences Partners

Subscribe to see more

Venture Capital

Netherlands

00/00/0000

00/00/0000

H.I.G. BioHealth Partners

Subscribe to see more

Venture Capital

Florida

First funding

1/4/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

1/4/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Andera Partners

NovaQuest Capital Management

Life Sciences Partners

H.I.G. BioHealth Partners

Rounds

1
Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporation

Private Equity

Private Equity

Venture Capital

Venture Capital

Location

Italy

France

North Carolina

Netherlands

Florida

Arvelle Therapeutics Investments

1 Investments

Arvelle Therapeutics has made 1 investments. Their latest investment was in SK Biopharmaceuticals as part of their Milestone Payment on February 2, 2019.

CBI Logo

Arvelle Therapeutics Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/18/2019

Milestone Payment

SK Biopharmaceuticals

$100M

Yes

1

Date

2/18/2019

Round

Milestone Payment

Company

SK Biopharmaceuticals

Amount

$100M

New?

Yes

Co-Investors

Sources

1

Arvelle Therapeutics Portfolio Exits

1 Portfolio Exit

Arvelle Therapeutics has 1 portfolio exit. Their latest portfolio exit was SK Biopharmaceuticals on July 02, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/2/2020

IPO

$99M

9

Date

7/2/2020

Exit

IPO

Companies

Valuation

$99M

Acquirer

Sources

9

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.